AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%

Trial Profile

AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms ADMIRE-ICD
  • Sponsors GE Healthcare
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Aug 2019 to 1 Aug 2021.
    • 04 Oct 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.
    • 28 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top